Shared Pathways Between Non-Alcoholic Fatty Liver Disease and Psoriatic Disease With Guselekumab Therapy
Stopped The sponsor determined that enrollment would not meet their expectations and decided to withdraw the study.
Conditions
- Psoriasis (PsO)
- PsA (Psoriatic Arthritis)
- NAFLD (Nonalcoholic Fatty Liver Disease)
Interventions
- DRUG: Guselkumab Prefilled Syringe [Tremfya]
Sponsor
University of California, San Diego
Collaborators